# Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer

> **NCT05673629** · PHASE3 · UNKNOWN · sponsor: **Beijing Biostar Pharmaceuticals Co., Ltd.** · enrollment: 552 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Utidelone Injection in combination with AC
- **DRUG:** Docetaxel Injection in combination with AC

## Key facts

- **NCT ID:** NCT05673629
- **Lead sponsor:** Beijing Biostar Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-30
- **Primary completion:** 2025-06-15
- **Final completion:** 2025-12-31
- **Target enrollment:** 552 (ESTIMATED)
- **Last updated:** 2023-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05673629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05673629, "Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05673629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*